Autres langues Clinuvel Pharmaceuticals Limited

Actions

CUV

AU000000CUV3

Produits pharmaceutiques

Marché Fermé - 08:10:27 04/09/2026 Varia. 5j. Varia. 1 janv.
8,150 AUD -1,33% Graphique intraday de Clinuvel Pharmaceuticals Limited -11,22% -34,59%

Autres langues

27/08 Clinuvel Pharmaceuticals Limited Declares Fully Franked Dividend for the Twelve Months Ended June 30, 2026, Payable on 18 September 2026
27/08 A decade of profitability provides foundation for CLINUVEL’s U.S. expansion
27/08 Clinuvel Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 30, 2026
27/08 Clinuvel Board Mulls Change to Group Structure, Potential Nasdaq Listing, ASX Delisting; Shares Dive 9%
27/08 Clinuvel Pharmaceuticals Fiscal 2026 Earnings, Revenue Down
12/08 Clinuvel Pharmaceuticals Ltd Advances Controlled-Release Injectable Liquid Peptide Platform Vlrx-L and Selects First Candidates for Further Preclinical Studies
12/08 Clinuvel Pharmaceuticals Identifies High-Potential Dose Formulations for Injectable Peptide Platform
30/07 Clinuvel Pharmaceuticals Ltd Provides Commercial Update On Vitiligo And Reports Clinical Benchmarks For SCENESSE
30/07 Clinuvel Pharmaceuticals Strengthens Supply Chain as Part of Commercial Preparations for North American Vitiligo Market
28/07 Clinuvel Pharmaceuticals Ltd Provides Update On SCENESSE In Vitiligo
28/07 Clinuvel Pharmaceuticals Plans to Report Late-Stage Vitiligo Study Topline Results in December
23/07 Clinuvel Pharmaceuticals Limited to Reduce Global Workforce by Approximately 10%-20%
23/07 Clinuvel Pharmaceuticals Limited Announces Relocation of Corporate Headquarters to the United States
23/07 CLINUVEL implements strategic reorganisation to refocus on U.S. markets
23/07 Clinuvel Pharmaceuticals to Move Headquarters to US, Plan Workforce Reduction of Up to 20%
23/07 Australian Shares Open Higher as Oil, Gold Rally on Middle East Tensions; Santos Posts Higher Q2 Total Production
21/07 Clinuvel Pharmaceuticals Confirms ADS Start Trading on Nasdaq
21/07 Clinuvel Pharmaceuticals Limited(NasdaqGS:CUVL) added to NASDAQ Composite Index
20/07 CLINUVEL’s ADS to commence trading on Nasdaq
20/07 Clinuvel Pharmaceuticals' ADS to Begin Trading on Nasdaq
13/07 Clinuvel Pharmaceuticals Limited Receives Health Canada Notice of Compliance for Scenesse for Prevention of Phototoxicity in Adult Patients with Erythropoietic Protoporphyria
13/07 SCENESSE® approved for EPP in Canada
13/07 Clinuvel Pharmaceuticals' Photoprotection Drug Candidate Receives Health Canada Approval
02/07 Clinuvel Pharmaceuticals Extends CEO Philippe Wolgen's Term of Employment
16/06 Clinuvel Pharmaceuticals Advances US Listing Plan With SEC Filing for Nasdaq ADS Upgrade
Aucun résultat pour cette recherche